Analysts at Maxim Group have initiated coverage of Momenta Pharmaceuticals, Inc. (MNTA) with a buy rating.
The firm set its price target on the stock at $24 a share, which is more than double its current market price.
Shares of MNTA are up 1% to $10.42 in the pre-market session, amid a 52-week trading range of $9.85 – $19.90.
Latest posts by Kevin Calderon (see all)
- Expedition 50 Of The ISS Just Broke Another Record - Apr 26, 2017
- Researchers Found Live Giant Shipworm That Feeds On Sulfur? - Apr 19, 2017
- Hawaiian Telescope Led To The Discovery Of A Primordial Galaxy - Apr 14, 2017